---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000059"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:20:45.106397+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics reports Q3 2023 net loss of $19.6M; Phase 2b/3 trial on track for Q2 2024 data

## Summary
- Net loss of $19.6M for Q3 2023, compared to $13.6M in Q3 2022; includes $3.2M stock-based compensation.
- R&D expenses rose to $16.9M from $10.8M YoY, driven by higher clinical trial and headcount costs.
- Cash, equivalents and securities totaled $135.2M at September 30, 2023, sufficient to fund operations into 2026.
- IMPAHCT Phase 2b/3 trial of AV-101 for PAH expects topline Phase 2b data in Q2 2024; over 125 sites active globally.

## SEC filing metadata
- accession: 0001798749-23-000059
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/0001798749-23-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/tmb-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000059
- JSON: https://secwatch.observer/filing/0001798749-23-000059.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000059.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported the quarter ended September 30, 2023 results: net income $19.6 million.
  - Period: the quarter ended September 30, 2023
  - Net income: $19.6 million
  - Result: reported results
  source text: Aerovate Therapeutics, Inc. announced its third quarter financial results and business highlights for the period ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/0001798749-23-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.